| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1893e58a79a78de604ff4b09e05c578b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate |
2022-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c25065800fd097c2206756f438b4eb2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6986a9e7898e18ebd3f44151c7761a63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c3c90133fab4d50200f416ab1bb61c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96387cc66f41032adb4d8bfbf6fdb9c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e1999726037e9a5a408abca98246ccd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41f584d3a1ca99d41befe5c99382b7de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eab1bdf59c9606a2802394501e900dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09cced43279151e26b984f851ee95ca9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c926ae23053c70d9de96d05ae413874
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a944882b4d839492aa1abb8ab2d14fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f452dc4ed04485f9899e3767a74caa9 |
| publicationDate |
2022-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022148968-A1 |
| titleOfInvention |
Anti-infective bicyclic peptide ligands |
| abstract |
The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly the spike protein S1 of SARS-CoV-2. The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by infection of SARS-CoV-2 or for providing prophylaxis to a subject at risk of infection of SARS-CoV-2. |
| priorityDate |
2021-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |